Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 173-180

  Bissery, Marie Christine ^a   Vrignaud, Patricia ^a   Lavelle, François ^a   Chabot, Guy G ^b  

^a SANOFI   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; IRINOTECAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CANCER GRAFT; CONFERENCE PAPER; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; SOLID TUMOR;

EID: 0030452954     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26386.x     Document Type: Conference Paper

References (35)

1. WALL, M. E., M. C. WANI, C. E. COOK, et al. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88: 3888-3890.
2. MUGGIA, F. M., P. J. CREAVEN, H. H. HANSEN, et al. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother. Rep. 56: 515-521.
3. KUNIMOTO, T., K. NITTA, T. TANAKA, et al. 1987. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47: 5944-5947.
4. BISSERY, M. C., A. MATHIEU-BOUÉ & F. LAVELLE. 1992. Experimental antitumor activity of CPT-11 in vitro and in vivo. Annals Oncol, 3: 82, abstract 93.
5. KAWATO, Y., T. FURUTA, M. AONUMA, et al. 1991. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol. 28: 192-198.
6. HOUGHTON, P. J., P. J. CHESHIRE, J. C. HALLMAN, et al. 1993. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxycamptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 53: 2823-2829.
7. VASSAL, G., J. MORIZET, M. C. BISSERY, I. BOLAND, P. ARDOUIN, A. MATHIEU-BOUÉ & A. GOUYETTE. 1994. Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblatoma xenografts. Proc. Am. Assoc. Cancer Res. 35: 366.
8. TSURUO, T., T. MATSUZAKI, M. MATSUSHITA, et al. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71-74.
9. HSIANG, Y. H., R. HERTZBERG, S. HECHT, et al. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14878.
10. HSIANG, Y. H. & L. F. LIU. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722-1726.
11. SLICHENMYER, W. J., E. K. ROWINSKY, R. C. DONEHOWER, et al. 1993. The current status of camptothecin analogues as antitumor agents (review). J. Natl. Cancer Inst. 85: 271-291.
12. HSIANG, Y. H., L. F. LIU, M. E. WALL, et al. 1989. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 49: 4835-4839.
13. SUGIMOTO, Y., S. TSUKAHARA, T. OH-HARA, et al. 1990. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50: 6925-6930.
14. TSUJI, T., N. KANEDA, K. KADO, et al. 1991. CPT-11 converting enzyme from rat serum: Purification and some properties. J. Pharmacobiodyn. 14: 341-349.
15. KANEDA, N., H. NAGATA, T. FURUTA, et al. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715-1720.
16. KAWATO, Y., M. AONUMA, Y. HIROTA, et al. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51: 4187-4191.
17. OHNO, R., K. OKADA, T. MASAOKA, et al. 1990. An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907-1912.
18. TAGUCHI, T., A. WAKUI, K. HASEGAWA. 1990. Phase I clinical study of CPT-11. Research Group of CPT-11. Jpn. J. Cancer Chemother. 17: 115-120.
19. NEGORO, S., M. FUKUOKA, N. MASUDA, et al. 1991. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst. 83: 1164-1168.
20. CATIMEL, G., G. G. CHABOT, J. P. GUASTALLA, et al. 1995. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Annals Oncol. 6: 133-140.
21. DE FORNI, M., R. BUGAT, G. G. CHABOT, et al. 1994. Phase I and pharmacokinetic study of the camptothecin derivative Irinotecan administered on a weekly schedule in cancer patients. Cancer Res. 54: 4347-4354.
22. FUKUOKA, M., H. MIITANI, A. SUZUKI, et al. 1992. A Phase II study of CPT-11, anew derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10: 16-20.
23. ABIGERGES, D., G. G. CHABOT, J. P. ARMAND, et al. 1995. Phase I and pharmacologic studies of the camptothecin analogue irinotecan (CPT-11) administered every three weeks in cancer patient. J. Clin. Oncol. 13: 210-221.
24. OHE, Y., Y. SASAKI, T. SHINKAI, et al. 1992. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84: 972-974.
25. SHIMADA, Y., M. YOSHINO, A. WAKUI, et al. 1993. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J. Clin. Oncol. 11: 909-913.
26. ROTHENBERG, M. L., J. G. KUHN, H. A. BURRIS III, et al. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194-2204.
27. ROWINSKY, E. K., L. GROCHOW, D. S. ETTINGER, et al. 1994. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54: 427-436.
28. CHABOT, G. G., D. ABIGERGES, G. CATIMEL, et al. 1995. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Annals Oncol. 6: 141-151.
29. BISSERY, M. C., P. VRIGNAUD, F. LAVELLE & G. G. CHABOT. 1996. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs. 7: 437-460.
30. CORBETT, T. H., A. WOZNIAK, S. GERPHEIDE & L. HANKA. 1985. A selective two-tumor soft agar assay for drug discovery. In In Vitro and in Vivo Models for Detection of New Antitumor Drugs. E. White, Ed.: 5-14. 14th International Congress of Chemotherapy. University of Tokyo Press, Tokyo. Japan.
31. CORBETT, T. H., W. R. LEOPOLD, D. J. DYKES, et al. 1982. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res. 42: 1701-1715.
32. CORBETT, T. H., M. C. BISSERY, P. MUCCI-LO RUSSO & L. POLIN. 1989. 5-fiuorouracil containing combinations in murine tumor systems. Investigational New Drugs 7: 37-49.
33. GERAN, R. I., N. H. GREENBERG, M. M. MACDONALD, et al. 1972. Protocols for screening chemical agents and natural products against animal tumors and other biological systems, third edition. Cancer Chemother. Rep. Part 3: 1-103.
34. RIOU, J. F., O. PETITGENET, I. AYNIÉ & F. LAVELLE 1994. Establishment and characterization of docetaxel (Taxotere®) resistant human breast carcinoma (Cale 18/TXT) and murine leukemic (P388/TXT) cell lines. Proc. Am. Assoc. Cancer Res. 35: 339 (Abstract).
35. BARILERO, I., D. GANDIA, J. P. ARMAND, et al. 1992. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography - Application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr. (Biomed. Appl.) 575: 275-280.